AstraZeneca's coronavirus vaccine trials determined safe to resume in U.K.


AstraZeneca announced Saturday that it received confirmation from the United Kingdom's Medicines Health Regulatory Authority that it was safe to resume clinical trials for the company's coronavirus vaccine in the U.K. after they were paused over safety concerns earlier this week. The statuses of trials elsewhere remain unclear, CNBC reports.
The vaccine candidate, which was developed in partnership between AstraZeneca and the University of Oxford, is considered one of the world's most promising, but phase three of its trials was temporarily halted after a woman in the U.K. reportedly displayed neurological symptoms consistent with a spinal inflammatory disorder called transverse myelitis after receiving the vaccine.
AstraZeneca isn't authorized to provide further medical information so the company statement didn't explicitly say whether the woman's illness was found to be unrelated to the vaccine, but Oxford said that during a large trial (18,000 people have received the vaccination so far) "it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety." Similarly, the World Health Organization's Chief Scientist Dr. Soumya Swaminathan said earlier this week that "these things happen" and there's no reason to be "overly discouraged" by the pause since "there are ups and downs in research." Read more at CNBC.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
August 23 editorial cartoons
Cartoons Saturday's political cartoons include deficit dimness, steamroller-in-chief, and more
-
5 museum-grade cartoons about Trump's Smithsonian purge
Cartoons Artists take on institutional rebranding, exhibit interpretation, and more
-
Settling the West Bank: a death knell for a Palestine state?
In the Spotlight The reality on the ground is that the annexation of the West Bank is all but a done deal
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC